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Background Despite high-quality evidence being
essential for planning and delivering eye health
programmes, evidence on what works is relatively scarce.
To address this need, we developed eye health Evidence
Gap Maps (EGMs) with the ﬁrst one focusing on
cataract. These maps summarise, critically appraise and
present evidence in a user-friendly format. This paper
presents experiences of developing the cataract gap map
and discusses the challenges and beneﬁts of the process.
Methods Following a comprehensive search of
relevant databases, we sifted and extracted data from all
relevant reviews on cataract. Critical appraisal was
conducted by two reviewers independently using
Supported the Use of Research Evidence checklist and a
summary quality assessment was shared with the
authors for comments.
Results A total of 52 reviews were included in the map.
The majority of the reviews addressed quality of clinical
care (20) and types of treatment (18). Overall, 30 reviews
provided strong evidence in response to the research
question, 14 reviews showed weak or no evidence and in
14 reviews the results were inconclusive. 14 reviews were
regarded as high quality, 12 were medium quality and 26
were graded as low quality. To verify the validity of the
Supporting the Use for Research Evidence (SURE)
checklist, studies were also appraised using the Scottish
Intercollegiate Guidelines Network (SIGN) tool. Based on
the κ statistics test, results showed excellent agreement
between the two checklists (K=0.79).
Discussion EGMs support policy makers and
programme managers to make informed decisions and
enable researchers to prioritise future work based on the
most evident gaps on knowledge.
BACKGROUND
Visual impairment
Visual impairment is a global health problem, with
an estimated 233 million people affected including
39 million who are blind.1 2 Around 65% of blind-
ness and 76% of moderate and severe visual
impairments (MSVIs) can be avoided through
timely access to prevention or treatment, but access
to such interventions in many low/middle-income
countries (LMICs) continues to be limited.1
Cataract is responsible for 33% of blindness and
18% of MSVIs globally, and a lack of access to
good quality eye health services is a key determin-
ant of avoidable vision loss due to cataract.3 Studies
among people with unoperated cataracts in
sub-Saharan Africa and Asia highlighted constraints
affecting both supply of (eg, number of qualiﬁed
health workers) and demand for services (eg, access
to services).4–9 Rigorous and relevant research evi-
dence is essential for planning cost-effective and
scalable approaches to deal with avoidable visual
impairment in resource-constrained environments.
Evidence on interventions that could be used to
improve eye health in LMICs is scarce, and there is
no single repository where all relevant research
may be found in a user-friendly format. Many
policy makers and clinicians plan their interven-
tions without the beneﬁt of the most up-to-date
knowledge, and patients may not be receiving the
best possible care available. Without a comprehen-
sive overview of existing evidence, current research
efforts may not be focusing on the most pressing
priorities with the most urgent evidence gaps.
Evidence gap maps
Evidence gap maps (EGMs) are a visual tool for
presenting the state of evidence in particular the-
matic areas relevant to international development,
with the aim to provide easy access to the best
available evidence and highlight knowledge gaps.
The approach was developed by the International
Initiative for Impact Evaluation (3ie) and has been
applied to a number of development areas includ-
ing water and education.10 11 Fundamentally, the
maps are matrices with interventions plotted
against outcomes. The evidence populating an
EGM can be drawn from any source, but many
existing EGMs synthesise evidence from systematic
and literature reviews. All evidence is assessed on
its relevance to LMICs, and the quality of the
review is appraised using a standardised quality
appraisal tool. All sources of evidence meeting pre-
deﬁned inclusion criteria are plotted in the map
cells corresponding to speciﬁc interventions. The
cells are linked to summary pages and show meth-
odological quality of the review using a trafﬁc light
system. A glance at the map clearly shows where
the evidence lies and where little evidence or poor
quality evidence exists. This paper describes experi-
ences and results of constructing the ﬁrst EGM in
eye health, which focused on cataract. The EGM
was developed by the international non-
governmental organisation (NGO) Sightsavers with
contributions from academic centres working in
the area of visual impairment, including Cochrane
Eyes and Vision group. The map is available online
and can be found in http://www.sightsavers.org/
gap-maps/cataract-gap-map/.
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METHODS
The process of constructing the cataract EGM is shown in
ﬁgure 1. As several reviewers were involved in the map develop-
ment, the key was to ensure consistency throughout the process.
Each author was assigned speciﬁc tasks for each stage of the
EGM development; additionally, the main author oversaw and
was involved in each activity. To avoid selection bias, two
authors independently screened the identiﬁed studies against the
predeﬁned inclusion criteria. Two reviewers independently
extracted data and followed a structured open-ended heading
alongside guidance on the content to extract from each review.
Critical appraisal was conducted using a standardised checklist
and guidelines for appraising.
Search strategies
The search strategy aimed to identify all published systematic
and literature reviews, including primary studies. To identify
relevant sources, we systematically searched several databases
including Cochrane Library, MEDLINE and EMBASE from
inception to the end of 2013 (see online supplementary
appendix A).
Additionally, we reviewed reference lists of the included
reviews and contacted the authors for information on other
relevant sources.
Sifting and selection
Titles and abstracts were reviewed independently by two
reviewers (from a team of two) against the predeﬁned selection
criteria:
▸ Systematic or literature reviews
▸ Reviews containing evidence from LMICs
▸ Reviews published between 1993 and 2013
▸ Reviews describing methods used for data collection and
synthesis
▸ Relevant to LMICs
The relevance was assessed by an ophthalmologist with sub-
stantial clinical experience in LMICs and a Sightsavers
researcher. Reviews were excluded if the search methodology
was restricted to high-income settings only, studies were narra-
tive reviews, published before 1993, or did not describe their
search and data synthesis methods.
Data extraction and strength of evidence
Two reviewers (from a team of seven) independently extracted
data of studies meeting the inclusion criteria and assessed meth-
odological quality of the reviews. A short summary describing
the key ﬁndings of each review and key points around the meth-
odology was developed.
Two researchers (from a team of two) independently analysed
the strength of evidence based on the ﬁndings and conclusions
reported by the authors. Evidence was categorised as strong if
the review found consistent strong evidence in response to the
research question or outcome; inconclusive if the review
reported mixed results; and weak if the review found weak or
no evidence in response to the research question or outcome.
Disagreement between the reviewers was resolved by discussion.
All data extraction and critical appraisal were in the original lan-
guage of the review. For reviews written in other languages,
reviewers were required to extract data and appraise it in
English. To ensure consistency, the main author conducted a
third review.
Quality appraisal
The methodological appraisal used an adapted version of the
Supporting the Use for Research Evidence (SURE) tool devel-
oped by the SURE collaboration (see online supplementary
appendix B).10 This checklist was used for all EGMs supported
by 3ie. The tool gives reviews an overall rating of high, medium
or low conﬁdence based on the assessment of three main
Figure 1 Overview of the cataract evidence gap map (EGM)
development.
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components : (1) methods used to identify, include and critically
appraise studies; (2) methods used to analyse the ﬁndings and
(3) reliability of the review.
Based on these, a summary of the methodological quality
assessment was produced reporting the overall conﬁdence attrib-
uted to the conclusions of the review. High conﬁdence was
attributed if all review methods were systematic and appropri-
ate, as speciﬁed in the appraisal checklist, and the risk of bias
was minimised. Medium conﬁdence was attributed if all or
some of the review methods were not systematic, as speciﬁed in
the appraisal checklist, but the methodological limitations were
acknowledged and taken into account in the conclusions of the
review. Low conﬁdence was attributed if overall review methods
were not systematic or appropriate, and the methodological lim-
itations were not acknowledged or taken into account in the
conclusions of the review. All appraisals were conducted by two
reviewers independently; if discrepancies were identiﬁed, a third
reviewer independently extracted data and appraised the review.
Authors of all included studies were contacted and provided
with the review quality appraisals for veriﬁcation. If the authors
were able to provide additional information to support a change
in the quality assessment, this was sent to the original reviewers
who again evaluated the paper independently.
To verify the validity of the SURE checklist for the purpose of
this assessment, we applied another critical appraisal tool (the
Scottish Intercollegiate Guidelines Network (SIGN) checklist) to
the English and Spanish language studies, compared the results
of the two appraisals and calculated the level of agreement
between the tools using the κ statistic test (K).12 Compared with
other critical appraisal tools, SIGN is the only one that assesses
the overall methodological quality of a paper and is therefore
comparable with the SURE checklist.
Scope and presentation of the cataract EGM
3ie EGMs visual presentation consists of interventions (y-axis)
against outcomes (x-axis). We modiﬁed this structure to ensure
that the cataract EGM clearly shows the strength of evidence
available and plotted the thematic areas assessed in the reviews
(x-axis) against the reviews’ strength of evidence (strong evi-
dence, weak evidence or mixed). We think this structure is more
appropriate for the EGMs, which display evidence on medical-
related thematic areas.
The way of organising the thematic areas reported in the
selected reviews was determined through a consultation
between the authors of the paper and two ophthalmologists
with substantial experience in eye health research in LMICs. As
a result, 14 thematic areas related to epidemiology and impact
of cataract, clinical care and health systems were agreed. The
term thematic area is used throughout the paper, as not all
included reviews reported an outcome measure or intervention.
Each review meeting the inclusion criteria was placed in the
cells corresponding to the relevant thematic area along the
x-axis and the strength of evidence reported in the conclusions
along the y-axis. Visually, each review is represented by a single
bubble, which links to the review summary page (http://www.
sightsavers.org/gap-maps/cataract-gap-map/). To enable users to
visually identify the quality of each review, a trafﬁc light system
was used. Green, orange and red bubbles represent high,
medium and low levels of conﬁdence in review conclusions,
respectively.
RESULTS
Of the 1197 unique studies identiﬁed, 52 systematic or literature
reviews were included in the cataract EGM (ﬁgure 2). Of the
included studies, six related to two interventions and were
included in the map twice, resulting in a total of 58 sources
depicted on the map.
The identiﬁed reviews were mostly written in English, three
were in Chinese, two were in German and two were in Spanish.
The majority of the reviews addressed quality of clinical care
(20) and types of treatment (18). Of the remainder, nine looked
at risk factors/prevention, ﬁve were economic evaluations and
three each addressed the burden of the disease and the accessi-
bility of cataract services (ﬁgure 3).
Overall, 30 reviews provided strong evidence in response to
the research question, 14 reviews showed weak or no evidence
and in 14 reviews the results were inconclusive. Out of 20
reviews examining clinical care, 12 concluded on the presence
of strong evidence, 6 showed no or weak evidence and in 2
reviews the results were mixed. In the treatment-related reviews,
the strength of evidence was equally split between strong, weak
and inconclusive categories.
Using the SURE checklist criteria, 16 reviews were regarded
as high quality, 13 were medium quality and 29 were graded as
low quality. The majority of high-quality reviews (38.9%) were
treatment-related, followed by quality of care, where a third of
the reviews were regarded as high quality. Among 30 reviews,
which showed the presence of strong evidence, 7 (23%) were
high quality and 16 (53.3%) were low quality. Among 14
reviews, which showed weak or no evidence in response to the
research question, 6 (42.8%) were high quality and 5 (35.7%)
were low quality. Among reviews examining clinical care, only 2
out of 12 reviews showing strong evidence were regarded as
high quality; among six reviews showing weak or no evidence,
four were high quality. Reviews were attributed low conﬁdence
mainly for not reporting the methods used to search the litera-
ture or to include studies or extract data, or for not conducting
comprehensive searches of the literature.
Clear gaps on evidence were identiﬁed on the broader aspects
of cataract-related health systems. No reviews were identiﬁed
for cataract-related screening, and very little evidence is available
on the impact of cataract interventions on economic productiv-
ity or quality of life. Only three reviews examined cost-
effectiveness of cataract-related interventions; all showed strong
evidence but the quality of the reviews were mixed (ﬁgure 4).
A total of 47 out of the 52 studies were appraised using both
the SURE and SIGN tools; two reviews written in German and
three in Chinese were excluded from the SIGN assessment. To
determine the extent of reproducibility and the level of agree-
ment between the two tools, we conducted a Kappa statistics
test (κ), which resulted in κ=0.79 indicating excellent agree-
ment between the two checklists. Comparison between tools
showed that approximately 93% of the reviews that were attrib-
uted high conﬁdence in conclusions using SURE were also rated
as high quality using SIGN. Sixty-eight per cent of the reviews
that were attributed low conﬁdence in conclusions using the
SURE checklist were rejected for further evaluation based on
the SIGN checklist appraisal (table 1, see online supplementary
table S1).
DISCUSSION
This paper describes results and experiences of developing the
ﬁrst gap map in eye health, which displays systematic review evi-
dence available on cataract. The majority of the reviews avail-
able synthesise evidence on different types of treatment and
aspects of clinical care. A smaller number of reviews examined
epidemiology, risk factors, access to services and cost-
effectiveness of cataract. Only two reviews synthesised evidence
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on impact of cataract interventions and none focused speciﬁcally
on cataract-related health systems.3 The conclusions on the
strength of evidence reported in the reviews and the rating of
the quality of the reviews themselves show mixed results.
With regard to the process of the EGM development, our
insights and observations are unique for two reasons. First, this
is the ﬁrst time the EGM approach was applied in the area of
eye health. Second, the development of the map was led by an
international NGO with contributions from academic institu-
tions, which provided opportunities for integration of both aca-
demic and practitioners’ perspective in the creation of the map.
In line with the experiences of others, we found EGMs to be
a useful tool for presentation of evidence applicable to a variety
of audiences, including policy makers and programme man-
agers. Although gap maps do not draw any conclusions or
recommendations for policy and practice per se, they allow
users to explore the availability and consistency of evidence and
to develop their own judgments and implications for practice.10
The EGMs should be analysed with caution to avoid misinter-
pretation. It is important to take into account that the cataract
EGM presented here displays evidence available through system-
atic and literature reviews only. Neither primary studies nor
impact evaluations were included in this EGM. The gaps in evi-
dence presented in our EGM do not necessarily imply the lack
of studies but the lack of systematic or literature reviews. It is
also important to distinguish between the areas where no evi-
dence exists and therefore more research is needed, and those
where primary studies are available but need to be synthesised
in a systematic review. As the EGM search strategy is usually
comprehensive and includes primary studies, integration of such
Figure 2 Documents identiﬁed through the search (from 29 July to 26 September 2013).
Figure 3 Thematic areas addressed by reviews included in the
cataract evidence gap maps (EGMs).
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additional sources of evidence into the same or a separate map
should be possible. However, as the process of appraising
studies can be very time consuming, this may be more
appropriate for the thematic areas where few systematic or lit-
erature reviews are available.
When considering evidence presented on the maps, users
should take into account the methodological quality of the
reviews included.13 Review authors of studies included in the
cataract EGM raised concerns about the validity of the SURE
checklist due to the lack of information on the validation of
this tool. The validation process involved appraising studies
included in the EGM using SIGN to assess the consistency and
reliability of the SURE checklist tool. Based on the kappa sta-
tistics test, results suggested that the SURE checklist is a valid
tool to appraise the quality of the reviews for the purpose of
EGMs. Implying rigorous development of the tool, items
included are based on empirical evidence and acceptable
reliability.14
Figure 4 Cataract evidence gap map (EGM).
Table 1 Results overview of the Supporting the Use for Research
Evidence (SURE) checklist validation exercise against the Scottish
Intercollegiate Guidelines Network (SIGN) checklist
SIGN checklist, number of studies
SURE checklist,
number of studies High quality Low quality Acceptable Rejected
Low quality, n=22 – 7 – 15
Medium quality, n=11 1 – 6 5
High quality, n=14 13 – 1 –
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It is important to understand that the appraisal of the quality
of the reviews for EGMs is based on the review methods
described in the publication and as per the criteria described in
the SURE checklist, which are relatively strict. Nevertheless, it is
important to note that the medium or low rating of the review
does not mean that the study conclusions are not valid. The
rating means that we are less conﬁdent that they are valid.
In conclusion, EGMs are a useful tool, which provides a
one-stop shop of evidence for global policy, advocacy, practice
and research. It is a tool through which relationships with
various stakeholders involved in international development can
be improved and strengthened.
Acknowledgements We show our appreciation to Catherine Pellegrino,
Heiko Philippin, Tingting Chen and Dr Xiao who contributed in the analysis of
reviews written in languages other than English. We also thank Kolawole
Ogundimu and Clare Gilbert for contributing towards the development of the
cataract platform.
Contributors BV contributed towards the conception and design; drafted the
manuscript and approved the ﬁnal version. EJ and ES contributed to the content of
the paper, reviewed it critically for substantial intellectual content and approved the
ﬁnal version. IG and CB provided their input towards the paper.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide,
1990-2010: a systematic analysis. Lancet Glob Health 2013;1:339–49.
2 Bastawrous A, Henning BD. The global inverse care law: a distorted map of
blindness. Br J Ophthalmol 2012;96:1357–8.
3 Blanchet K, Gordon I, Gilbert CE, et al. How to achieve universal coverage of
cataract surgical services in developing countries: lessons from systematic reviews of
other services. Ophthalmic Epidemiol 2012;19:329–39.
4 Athanasiov PA, Casson RJ, Newland HS, et al. Cataract surgical coverage and
self-reported barriers to cataract surgery in a rural Myanmar population.
Clin Experiment Ophthalmol 2008;36:521–5.
5 Athanasiov PA, Edussuriya K, Senaratne T, et al. Cataract in central Sri Lanka:
cataract surgical coverage and self-reported barriers to cataract surgery.
Clin Experiment Ophthalmol 2009;37:780–4.
6 Vaidyanathan KLH, Foster A, Pandey RM. Changing trends in barriers to cataract
surgery in India. Bull World Health Organ 1999;77:104–9.
7 Chandrashekhar TS, Bhat HV, Pai RP, et al. Coverage, utilization and barriers to
cataract surgical services in rural South India: results from a population-based study.
Public Health 2007;121:130–6.
8 Gyasi ME, Amoaku WMK, Asamany DK. Barriers to cataract surgical uptake in the
Upper East Region of Ghana. Ghana Med J 2007;41:167–70.
9 Rabiu MM. Cataract blindness and barriers to uptake of cataract surgery in a rural
community of northern Nigeria. Br J Ophthalmol 2001;85:776–80.
10 Snilstveit B, Vojtkova M, Bhavsar A, et al. Evidence gap maps—a tool for
promoting evidence-informed policy and prioritizing future research. Policy Research
working paper no. WPS 6725. Washington DC: World Bank Group, 2013.
11 International Initiative for Impact Evaluation. Evidence Gap Maps. http://www.
3ieimpact.org/evaluation/evidence-gap-maps/ (accessed 19 Oct 2015).
12 Kirkwood BR, Sterne JAC. Essential medical statistics. Blacwell Publishing Ltd,
2003:433–7.
13 Burls A. What is critical appraisal? London, UK: Evidence Based Healthcare, 2009.
http://www.whatisseries.co.uk/what-is-critical-appraisal/.
14 Cluzeau FA, Littlejohns P, Grimshaw JM, et al. Development and application of a generic
methodology to assess the quality of clinical guidelines. Int J Qual Care 1999;11:21–8.
1460 Virendrakumar B, et al. Br J Ophthalmol 2016;100:1455–1460. doi:10.1136/bjophthalmol-2015-308156
Review
